X

Drug Profile

P01KRASG12C 02

Alternative Names: P 01 KRASG12C 02; P01KRASG12C_02

Latest Information Update: 17 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PRAMOMOLECULAR
Class Antineoplastics; Drug conjugates; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Gastrointestinal cancer

Most Recent Events

13 Oct 2023 Early research in Gastrointestinal cancer in Germany (Parenteral) prior to October 2023 (PRAMOMOLECULAR pipeline, October 2023)
07 Jul 2022 PRAMOMOLECULAR has worldwide patent pending for modified nucleic acid conjugates

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com